ArticleCommunications biology2025
CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarial.
Geeta Kumari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it